1381. Deputy Louis O'Hara asked the Minister for Health the steps being taken to ensure hormone replacement therapy (HRT) medicine alternatives such as evorel are included in the free HRT scheme, especially given the possible long-term unavailability of estradot; if her Department or the HSE plans to reassess the coverage of such alternative HRT medication under the free HRT scheme to ensure continuity of care; and i…
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
1450. Deputy David Cullinane asked the Minister for Health if she is aware of a shortage of a skin cancer drug efudix through pharmacies; the action being taken by her Department in relation to same; and if she will make a statement on the matter. [29703/25]
1467. Deputy Colm Burke asked the Minister for Health if she is concerned by the latest data from the EFPIA Patient Wait Indicator 2024, indicating an average wait time of 645 days for access to new medicines in Ireland, which constitutes a further disimprovement on last year's figures; to outline what plans are underway to improve the structures and speed of the system, in line with the Programme for Government comm…
1468. Deputy Colm Burke asked the Minister for Health if the 34 new whole-time equivalent positions for the agencies involved in the HSE's medicines pricing and reimbursement system, as initially prescribed in February 2023 by the then-Minister for Health, have now been successfully filled; whether they have commenced their engagement; and if she will make a statement on the matter. [29792/25]
1470. Deputy Colm Burke asked the Minister for Health her views on the findings of a report (details supplied) in relation to the development of a system of transferable exclusivity vouchers; whether she is supportive of the introduction of such a system at Irish and EU level; and if she will make a statement on the matter. [29794/25]
1479. Deputy Shane Moynihan asked the Minister for Health to outline the availability of estradot in Ireland, and if an alternative to this drug can be funded as part of the free HRT programme. [29831/25]
1481. Deputy Pádraig Rice asked the Minister for Health the reason for the delay in commencing the inquiry into the historical licensing and use of sodium valproate; the work carried out to date; the timeline for formal commencement; and if she will make a statement on the matter. [29835/25]
1511. Deputy Pádraig Rice asked the Minister for Health the number of patients receiving biologics medicines for severe asthma in 2024 and to date in 2025; and the specific biologic medicines included, in tabular form. [29978/25]
1512. Deputy Pádraig Rice asked the Minister for Health the number of patients receiving biologic medicines for severe asthma in 2024 and to date in 2025, by health region and hospital, in tabular form. [29979/25]
1513. Deputy Pádraig Rice asked the Minister for Health the status of the commissioned managed access protocol necessary for the reimbursement of a severe asthma biologic medicine for patients with EOS level greater than 300 (details supplied); the delivery timeline; and if she will make a statement on the matter. [29980/25]
1514. Deputy Pádraig Rice asked the Minister for Health the status of the health technology assessment ongoing with the National Centre for Pharmacoeconomics for a biologic medicine to be used for severe asthma patients with EOS level less than 300 (details supplied); the delivery timeline; and if she will make a statement on the matter. [29981/25]
1523. Deputy Barry Heneghan asked the Minister for Health if work has begun to explore early access schemes for certain medicines, as outlined in the Programme for Government; the person in her Department that will have responsibility for this work; if this will include a review of early access schemes already operating in other European countries; and if she will make a statement on the matter. [30015/25]
1551. Deputy Brian Stanley asked the Minister for Health further to Parliamentary Question No. 787 of 20 May 2025, around the reimbursement list scheme, the answer states that liraglutide (saxenda) is the only product currently approved under community drug schemes GMS/DPS for weight management, to clarify the criteria for use; if a person needs to be in diagnosis of prediabetes or can other factors such as high card…
1629. Deputy Claire Kerrane asked the Minister for Health when a drug (details supplied) will be available on the drugs payment scheme to ensure that for those unable to take any form of HRT, now free, can access the alternative for free; and if she will make a statement on the matter. [30656/25]
545. Deputy Noel McCarthy asked the Minister for Health to outline if VYLOY (zolbetuximab-clzb) is currently being reviewed for inclusion in the HSE reimbursement scheme; the status of such a review; and if she will make a statement on the matter. [28541/25]
646. Deputy David Cullinane asked the Minister for Health the estimated cost of reducing the drug payment scheme threshold in increments of €5 to €0, in tabular form. [28743/25]
674. Deputy Conor Sheehan asked the Minister for Health if weight-loss drugs such as ozempic and mounjaro will be made available to medical card patients; her views on whether they should; and if she will make a statement on the matter. [28848/25]
680. Deputy Pádraig Mac Lochlainn asked the Minister for Health if she will advise on a matter raised in correspondence (details supplied). [29078/25]
663. Deputy Brian Stanley asked the Minister for Health if combivent/pulmicort is covered under the GMS Scheme; if not, the reason for its removal; and if she will make a statement on the matter. [26941/25]
681. Deputy Ruth Coppinger asked the Minister for Health if she is aware of a shortage of Ipratropium Steri Neb (Ipramol), Salbutamol, and Atrovent; and if attempts have been made to address this, in light of the dangerous consequences for those reliant on this medication. [26993/25]
767. Deputy James O'Connor asked the Minister for Health if urgent approval will be granted for vyloy (zolbetuximab) which is used for certain types of gastric and gastroesophageal junction cancers (details supplied); and if she will make a statement on the matter. [27575/25]
769. Deputy Pádraig O'Sullivan asked the Minister for Health if she will consider for reimbursement the new treatment VYLOY (zolbetuximab), which is used for certain types of gastric and gastroesophageal junction cancers; and if she will make a statement on the matter. [27585/25]
800. Deputy Pádraig Rice asked the Minister for Health if a drug will be made available to patients for certain types of gastric and gastroesophageal junction cancers under the HSE reimbursement scheme (details supplied); and if she will make a statement on the matter. [27684/25]
802. Deputy Holly Cairns asked the Minister for Health the reason vyloy, also called zolbetuximab, (details supplied) is not currently reimbursed by the HSE under the drug payment scheme despite being approved by the European Medicines Agency; and if she will make a statement on the matter. [27689/25]
805. Deputy Pat Buckley asked the Minister for Health for a fast-tracked review of vyloy (zolbetuximab), which is used for certain types of gastric and gastroesophageal junction cancers, for inclusion in the HSE reimbursement scheme. [27703/25]